CompletedPhase 2

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Germany103 participantsStarted 2017-12-15

Plain-language summary

The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. are asymptomatic and
✕. have no requirement for steroids 6 weeks prior to start of study treament. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases 7. Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.

What they're measuring

overall survival (OS)

Timeframe: up to 57 months from randomization

Trial details

NCT IDNCT03317457

SponsorAIO-Studien-gGmbH

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-08-12

View on ClinicalTrials.gov More Metastatic Adult Soft Tissue Sarcoma trials